Karnataka has ordered hospitals and medicine sellers to show procurement cost, MRP and patient price on bills from November 1. The move aims to improve billing transparency, though industry and patient groups say enforcement and wider supply-chain tracking will matter.
Karnataka has become the first Indian state to mandate disclosure of the actual procurement cost, or landing price, of medicines, medical devices and consumables alongside their maximum retail price and the amount charged to patients. The state’s Food Safety and Drugs Administration has directed healthcare institutions and medicine retailers to make these prices visible on patient bills from November 1, bringing a long-standing concern over healthcare pricing into sharper focus.
The circular seeks to address the gap between what hospitals pay to procure products and what patients are charged. It notes that patients are frequently billed at or near the MRP without any awareness of the actual acquisition cost. The directive covers government, private and trust hospitals, nursing homes, clinics, day-care centres, diagnostic facilities, and all licensed distributors, wholesalers, and retailers across the state.
Under the updated requirements, every patient must receive an itemised bill separating medicines, medical devices, implants, consumables, and disposables. Each line item must feature the product name, batch number, manufacturing and expiry dates, landing or base price, MRP, final price charged, and applicable taxes, while ensuring the billed amount does not exceed the MRP.
This regulatory step arrives amid sustained national scrutiny regarding medical product pricing. A recent parliamentary committee report highlighted major gaps between acquisition costs and final patient charges, while the Maharashtra Food and Drug Administration also raised concerns regarding steep hospital mark-ups. Furthermore, the Supreme Court has previously questioned authorities over hospital and medicine pricing dynamics, and the central government recently capped trade margins for non-scheduled cancer drugs.
While advocates for patient rights support the initiative for allowing individuals to better examine bills and question unexpected charges, they caution that disclosing procurement prices does not inherently lower costs or provide immediate alternatives during active treatment. Meanwhile, the Association of Indian Medical Device Industry has welcomed the policy as a constructive measure for accountability, though it contends that transparency must trace the entire supply chain.
Industry representatives suggest that tracking prices from initial manufacturing or import points through every intermediary tier, including distributors and stockists, is necessary to accurately identify where excessive mark-ups occur. The association has also urged federal authorities to engage in broad stakeholder consultations and pilot programs before implementing wider margin rationalisation measures.